bioMérieux: completes acquisition of Specific Diagnostics

(CercleFinance.com) - bioMérieux today announced that it has completed the acquisition of Specific Diagnostics, a US company that has developed a rapid antibiotic susceptibility testing system that provides a phenotypic antibiotic susceptibility test (AST) directly from positive blood cultures.


The French group acquired the company for a price equivalent to 3.2% of its own market capitalisation, in a combination of cash and 1,288,901 new shares issued to certain Specific Diagnostics shareholders.

bioMérieux will shortly launch a share buyback program to offset this dilution. With this acquisition, the in-vitro diagnostics specialist plans to expand its global leadership in clinical microbiology.


Copyright (c) 2022 CercleFinance.com. All rights reserved.